[1]黄雪平,王明霞,江丽凤,等.慢性乙型肝炎病毒感染患者血清sPD-1检测的临床意义[J].福建医药杂志,2022,44(03):8-11.
　HUANG Xueping,WANG Mingxia,JIANG Lifeng,et al.Detection and clinical significance of soluble programmed death factor-1 in patients with chronic viral hepatitis B[J].FUJIAN MEDICAL JOURNAL,2022,44(03):8-11.
点击复制

慢性乙型肝炎病毒感染患者血清sPD-1检测的临床意义()
分享到：

《福建医药杂志》[ISSN:1002-2600/CN:35-1071/R]

卷:
44
期数:
2022年03期
页码:
8-11
栏目:
临床研究
出版日期:
2022-06-15

文章信息/Info

Title:
Detection and clinical significance of soluble programmed death factor-1 in patients with chronic viral hepatitis B
文章编号:
1002-2600(2022)03-0008-04
作者:
黄雪平; 王明霞; 江丽凤1; 陆玉萍; 林志辉2
福建医科大学省立临床医学院 福建省立医院消化内科(福州 350001)
Author(s):
HUANG Xueping;  WANG Mingxia;  JIANG Lifeng;  LU Yuping;  LIN Zhihui
Department of digestive internal medicine,Fujian Provincial Hospital,Provincial Clinical Medical College of Fujian Medical University,Fuzhou,Fujian 350001,China
关键词:
可溶性程序性死亡因子-1;  乙型肝炎;  肝癌;  抗病毒
Keywords:
soluble programmed death factor-1;  hepatitis B;  hepatocellular carcinoma;  antiviral
分类号:
R512.6+2
文献标志码:
B
摘要:
目的 探讨血清中可溶性程序性死亡因子-1(sPD-1)在慢性乙型肝炎病毒(HBV)感染患者中检测的临床意义。方法 选择我院就诊的慢性HBV感染非肝癌患者41例(慢性HBV感染组)和乙型肝炎性肝癌(HCC)患者59例(HCC组),采用ELISA技术检测两组血清sPD-1的水平。比较sPD-1在慢性HBV感染组和HCC组之间及HCC组肝癌手术前后差异,分析慢性HBV感染患者sPD-1水平与性别、年龄、抗病毒治疗等因素的关系。结果 慢性HBV感染患者血清sPD-1为94.0(85.0,128.0)pg/mL,而乙型肝炎性肝癌患者血清sPD-1为28(9.0,44.5)pg/mL,差异有统计学意义(P<0.001)。sPD-1在肝癌与HBV感染非肝癌患者之间具有明显鉴别作用,其截断值为63 pg/mL(AUC:0.916,P<0.001)。肝癌患者sPD-1水平从切除前的106(43,120)pg/mL下降至切除后2天的91(34,100)pg/mL,差异有统计学意义(P<0.001)。慢性HBV感染抗病毒组sPD-1水平[(111.37±59.13)pg/mL]明显低于未抗病毒组[(306.09±59.13)pg/mL],差异有统计学意义(P=0.025)。慢性HBV感染sPD-1水平与年龄呈负相关(r=-0.82,P<0.05),与性别等其他因素无明显关联(P>0.05)。结论 sPD-1在慢性HBV感染和肝癌的发生中可能发挥了一定的作用; 监测血清sPD-1值,可能有助于预测乙型肝炎性肝癌的发生,对肝癌有鉴别诊断的价值。
Abstract:
Objective To investigate the clinical significance of serum soluble programmed death-1(sPD-1)detection in patients with chronic hepatitis B virus(HBV)infection. Methods A total of 41 patients with chronic HBV infection without liver cancer(chronic HBV infection group)and 59 patients with HBV-induced hepatic carcinoma(HCC group)who were treated in our hospital were selected, and the serum sPD-1 levels in the two groups were detected by ELISA. sPD-1 of chronic HBV infection group and HCC group, as well as that before and after surgery in HCC group were compared, and the relationship between sPD-1 level and gender, age, antiviral therapy and other factors in patients with chronic HBV infection was analyzed. Results The serum sPD-1 of patients with chronic HBV infection was 94.0(85.0, 128.0)pg/mL, while the serum sPD-1 of patients with HCC was 28(9.0, 44.5)pg/mL, the difference was statistically significant(P<0.001). sPD-1 has a distinct role in discriminating between HCC and HBV-infected non-HCC patients, with a cut-off value of 63 pg/mL(AUC: 0.916, P<0.001). The level of sPD-1 in patients with HCC decreased from 106(43,120)pg/mL before resection to 91(34,100)pg/mL two days after resection, and the difference was statistically significant(P<0.001). The level of sPD-1 in the antiviral group of chronic HBV infection(111.37±59.13)pg/mL〗 was significantly lower than that in the non-antiviral group(306.09±59.13)pg/mL, and the difference was statistically significant(P=0.025). The level of sPD-1 in chronic HBV infection was negatively correlated with age(r=-0.82, P<0.05), and had no significant correlation with other factors such as gender(P>0.05). Conclusion sPD-1 may play a certain role in the occurrence of chronic HBV infection and HCC. Monitoring serum sPD-1 value may help to predict the occurrence of HCC and has the value of differential diagnosis of HCC.

参考文献/References:

[1] Ott J J, Stevens G A, Groeger J, et al.Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity[J].Vaccine, 2012,30(12):2212-2219.
[2] Lozano R, Naghavi M, Foreman K, et al.Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010[J].Lancet, 2012,380(9859):2095-2128.
[3] Ohaegbulam K C, Assal A, Lazar-Molnar E, et al.Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway[J].Trends Mol Med, 2015,21(1):24-33.
[4] La X, Zhang F, Li Y, et al.Upregulation of PD-1 on CD4(+)CD25(+)T cells is associated with immunosuppression in liver of mice infected with Echinococcus multilocularis[J].Int Immunopharmacol, 2015,26(2):357-366.
[5] 段雪飞.中国《慢性乙型肝炎防治指南(2015版)》要点解读[J].中华全科医师杂志, 2016,15(6):409-412.
[6] Duan S, Zhang G, Han Q, et al.CTLA-4 exon 1 +49 polymorphism alone and in a haplotype with -318 promoter polymorphism may confer susceptibility to chronic HBV infection in Chinese Han patients[J].Mol Biol Rep, 2011,38(8):5125-5132.
[7] Mohammadzadeh S, Khanahmad H, Esmaeil N, et al.Producing Soluble Human Programmed Cell Death Protein-1: A Natural Supporter for CD4+T Cell Cytotoxicity and Tumor Cells Apoptosis[J].Iran J Biotechnol, 2019,17(4):e2104.
[8] Onlamoon N, Rogers K, Mayne A E, et al.Soluble PD-1 rescues the proliferative response of simian immunodeficiency virus-specific CD4 and CD8 T cells during chronic infection[J].Immunology, 2008,124(2):277-293.
[9] 范德环, 张学光, 奚沁华, 等.人可溶性PD-1在肝病患者血清中表达检测及临床意义[J].免疫学杂志, 2015,31(9):799-802.
[10] Zhou L, Li X, Huang X, et al.Soluble programmed death-1 is a useful indicator for inflammatory and fibrosis severity in chronic hepatitis B[J].J Viral Hepat, 2019,26(7):795-802.

备注/Memo

备注/Memo:
基金项目:福建医科大学启航基金(2016QH108)
1 中山大学附属第五医院医保科; 2 通信作者,Email: 491589958@qq.com
更新日期/Last Update: 2022-06-15